Speakers
Andrew V. Schally, University of Miami, USA
Title: TBA
Techn. Wassil Nowicky, Ukrainian Anti-Cancer Institute,Austria
Title: The proton preparation NSC-631570 (UKRAIN) and its selective effect
Carolyn Compton, Arizona State University, Arizona, USA
Title: Specimens, Standards, and Signatures: Keys to the Vision of Precision Medicine
Olivier E Pardo, Imperial College, London
Title: Resistance to tyrosine kinase-targeted therapy in lung cancer: autophagy and metabolic changes
Graham Pawelec, University of Tuebingen Center for Medical Research (ZMF), Germany
Title: Immunotherapy of Cancer: triumphs and challenges and the impact of immunosenescence
Thomas Sayers, NIH/NCI Frederick, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, USA
Title: Targeting caspase-8-dependent apoptosis in cancer cells to enhance immunotherapy
Olivier Dormond, CHUV, Swizterland
Title: Role of mTOR in the tumor endothelium
Myron R Szewczuk, Queen's University, Kingston, Ontario, Canada
Title: Pancreatic cancer dictates an inflammatory mediated tumorigenesis in the host microenvironment
Indraneel Mittra, Tata Memorial Centre, India
Title: Biology of cell-free nucleic acids and their role in initiation, progression and metastasis of cancer
Kazuko Tatsumura, Gaia Holistic Health, USA
Title: Effects of Far-Infrared & Terahertz Onnetsu Therapy on Rheumatoid Arthritis and Various Cancers
Chellappan Srikumar, Moffitt Cancer Center & Research Institute, USA
Title: YAP1 as a therapeutic target: Novel regulatory mechanisms in tumor angiogenesis
Shahram Kordasti, King’s College London,UK
Title: Cancer immune-monitoring; challenges of big data management
Mukerrem Betul Yerer Aycan, University of Erciyes, Turkey
Title: Therapeutic resistance in cancer: role of quercetin
Li Zhang, The University of Texas at Dallas, USA
Title: Heme and vascular disrupting agent in non-small cell lung cancer
Isaura Meza, CINVESTAV-IPN, Mexico
Title: IL-1-activated signaling pathways induce resistance to cisplatin through ∆NP63 in breast cancer cells
Paolo Ceppi, Uniklinikum Erlangen, IZKF Junior Group 1, Nikolaus-Fiebiger-Zentrum, Germany
Title: Polyol pathway as a novel therapeutic target for aggressive tumors
Khosrow Kashfi, City University of New York School of Medicine, USA
Title: Building better and safer NSAIDs: Development and therapeutic potential of hybrids that release nitric oxide and hydrogen sulfide
Marek K. Janiak, Military Institute of Hygiene and Epidemiology, Poland
Title: Cancer immunotherapy with low-level whole-body exposures to ionizing radiation
Betul Karademir, School of Medicine, University of Marmara, Turkey
Title: Second generation proteasome inhibitors: Side effects and potency in cancer therapy
Per thor Straten, University Hospital Herlev, University of Copenhagen, Denmark
Title: T cell co-stimulation vulnerable to breach by cancer cells in the tumor microenvironment
Zeliha Esin Celik, Selcuk University TURKEY
Title: Association of Ring Box-1 Protein Overexpression With Clinicopathologic Prognostic Parameters in Prostate Carcinoma
Mónica A. Costas, Universidad de Buenos Aires, Argentina
Title: High RAC3 expression levels are required for induction and maintaining of cancer cell stemness
Serge Y Fuchs, University of Pennsylvania, USA
Title: Inactivation of type I interferon pathway as a critical determinant of immune suppressive tumor microenvironment
Bessi Qorri, Queen's University, Kingston, Ontario, Canada
Title: Targeting Neuraminidase-1 with multi-modal therapy to sensitize pancreatic cancer to chemotherapy and moderate the inflammatory microenvironment
Nicka Kalaydina, Queen's University, Kingston, Ontario, Canada
Title: Aspirin, oseltamivir phosphate, and metformin sensitize 3D triple-negative breast cancer spheroids to tamoxifen treatment
Maria Fiammetta Romano, University of Naples Federico, Italy
Title: Co-inhibitory immune signaling generates the splicing of an immunophilin which marks a highly suppressive Tregs subset
Yuan Yuan, City Of Hope, USA
Title: CDK 4/6 inhibitors beyond estrogen receptor positive breast cancer: synergistic effect of PI3K and CDK4/6 in triple negative breast cancer
Lisa McGee, Mayo Clinic Arizona, USA
Title: Postmastectomy chest wall reirradiation with proton therapy for breast cancer
Larysa M Skivka, Taras Shevchenko National University of Kyiv,Ukraine
Title: Selective anti-cancer drug NSC631570 re-educates alternatively activated phagocytes
Gray Kueberuwa, The University of Manchester, UK
Title: Tumour infiltrating lymphocyte therapy; melanoma and beyond
Sarah Prinsloo, The University of Texas MD Anderson Cancer Center, USA
Title: Biomarker Identification and Neuromodulation as Treatment for Chronic Chemotherapy-Induced Peripheral Neuropathy
Chiara Recchi, Imperial College of London, UK
Title: The tumour suppressor OPCML prevents AXL-mediated EMT and motility in ovarian cancer cells
Dae Ro Lim, Soonchunhyang University Bucheon Hospital, Korea
Title: TBA
Jehad Zweiri, University of Liverpool Medical School, UK
Title: Cancer Vaccines and the impact of g-irradiation on the induction of bystander killing by genetically engineered ovarian tumor cells: implications for clinical use
Gopal C. Kundu, National Centre for Cell Science, India
Title: Therapeutic Targeting of Osteopontin and Integrin in Triple Negative Breast Cancer
Dumitru A Iacobas, Prairie View A&M University,TX, USA
Title: Gene Master Regulators and the Personalized Timely Cancer Gene Therapy
Ella L. Kim, Johannes Gutenberg University Medical Center, Germany
Title: Towards personalized medicine for patients with recurrent malignant brain tumours
Hang Fai Kwok, University of Macau, Macau SAR
Title: Anti-TACE antibody drug development for the treatment of cancer
Georg Voelcker, Goethe University Frankfurt Medical School, Frankfurt, Germany
Title: Synergistic interaction of cancer-reductive and anti-tumor driven immunotherapeutic activity of a new class of oxazaphosphorine cytostatics
Jaya Padmanabhan, H. Lee Moffitt Cancer Center and Research Institute, FL, USA
Title: Targeting transcription-associated cdks is an effective strategy to combat glioblastoma and medulloblastoma with minimal effect on primary neurons
Bulent Ozpolat, MD Anderson Cancer Center, The University of Texas-Houston TX, USA
Title: Development of Novel targeted therapies for Breast Cancers
Mahbub AA, Umm Al Qura University, King Saudi Arabia
Title: Polyphenols Act Synergistically with Doxorubicin and Etoposide in Leukemia Cell Lines